The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2011Xenon inhalation to reduce L-Dopa-induced dyskinesia
Objective/Rationale:
Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling levodopa-induced dyskinesia (LID) in the vast majority of... -
Therapeutics Development Initiative, 2011Pharmacokinetics and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated Pre-clinical Models
Promising Outcomes of Original Grant:
The goal of our original project was to determine if a prodrug of acamprosate could inhibit levodopa-induced dyskinesias (LIDs) in a pre-clinical model. During... -
LRRK2, 2011The Role of LRRK2 in Regulating a Calcium-Dependent Pathway Involving Lysosomal Stores and NAADP
Objective/Rationale:
Our preliminary evidence indicates that LRRK2 may regulate acidic calcium stores, with downstream effects on autophagy as well as a variety of other calcium dependent cellular... -
Target Validation, 2011Tau Oligomers as a Potential Target for Treatment of Parkinson's Disease
Objective/Rationale:
Tau pathology is a prominent feature of synucleinopathies, such as Parkinson disease (PD) and dementia with Lewy Bodies (DLB). An emerging view in neurodegeneration is that... -
MJFF Research Grant, 2011Generation of Monoclonal and Polyclonal Antibodies against LRRK1
Objective/Rationale:
There is great excitement that drugs targeting an enzyme called LRRK2 may have utility in the treatment of Parkinson’s disease. Some companies are attempting to develop LRRK2... -
MJFF Research Grant, 2011Generation of Monoclonal and Polyclonal Antibodies Against Aggregated Forms of Alpha-Synuclein
Objective/Rationale:
The aggregation of alpha-synuclein plays a pivotal role in the development of Parkinson’s disease. This subproject focuses on supporting the MJFF initiative of generating...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.